A detailed history of Platinum Investment Management LTD transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Platinum Investment Management LTD holds 41,508 shares of PRTA stock, worth $846,348. This represents 0.04% of its overall portfolio holdings.

Number of Shares
41,508
Previous 41,508 -0.0%
Holding current value
$846,348
Previous $1.51 Million 31.83%
% of portfolio
0.04%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$52.05 - $65.0 $385,482 - $481,390
-7,406 Reduced 15.14%
41,508 $2.5 Million
Q3 2022

Nov 14, 2022

SELL
$25.16 - $60.63 $291,805 - $703,186
-11,598 Reduced 19.17%
48,914 $2.97 Million
Q3 2021

Nov 09, 2021

SELL
$48.2 - $78.89 $2 Million - $3.27 Million
-41,393 Reduced 40.62%
60,512 $4.31 Million
Q2 2021

Aug 11, 2021

SELL
$21.63 - $57.65 $569,258 - $1.52 Million
-26,318 Reduced 20.53%
101,905 $5.24 Million
Q1 2020

May 15, 2020

SELL
$7.54 - $15.77 $95,908 - $200,594
-12,720 Reduced 9.02%
128,223 $1.37 Million
Q4 2019

Feb 13, 2020

SELL
$7.48 - $17.01 $366,879 - $834,306
-49,048 Reduced 25.82%
140,943 $2.23 Million
Q2 2019

Aug 14, 2019

BUY
$8.85 - $12.49 $249,083 - $351,531
28,145 Added 17.39%
189,991 $2.01 Million
Q4 2018

Feb 14, 2019

BUY
$8.73 - $13.74 $232,619 - $366,116
26,646 Added 19.71%
161,846 $1.67 Million
Q2 2018

Aug 15, 2018

BUY
$10.99 - $44.21 $626,430 - $2.52 Million
57,000 Added 72.89%
135,200 $1.97 Million
Q1 2018

May 15, 2018

BUY
$27.95 - $45.04 $218,010 - $351,312
7,800 Added 11.08%
78,200 $2.87 Million
Q4 2017

Feb 15, 2018

BUY
$35.44 - $63.76 $297,696 - $535,584
8,400 Added 13.55%
70,400 $2.64 Million
Q3 2017

Nov 14, 2017

SELL
$53.83 - $67.75 $242,235 - $304,875
-4,500 Reduced 6.77%
62,000 $4.02 Million
Q2 2017

Aug 15, 2017

BUY
N/A
66,500
66,500 $3.6 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $957M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Platinum Investment Management LTD Portfolio

Follow Platinum Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Platinum Investment Management LTD with notifications on news.